北京健康(02389.HK):2022年母公司擁有人應占虧損9769.6萬港元
格隆匯3月30日丨北京健康(02389.HK)發佈公吿,截至2022年12月31日止年度,收入為1.66億港元,同比下降18.3%;母公司擁有人應占虧損9769.6萬港元,同比擴大147.9%;基本每股虧損1.61港仙。
2022年度,集團整體毛利率為27.9%,而去年同期則為23.1%,輕微上升4.8%,主要由於集團主動調整產品及客户結構,減低毛利率較低的房地產客户訂單,繼而增加利潤較高的教育行業客户訂單,如本年新增的多所大學訂單。因此,即使本年度銷售額下跌,集團仍然錄得約4651.2萬港元的毛利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.